

# Application News

**Liquid Chromatograph Mass Spectrometry** 

# Multi-Residue Veterinary Drug Analysis of >200 Compounds using MRM Spectrum Mode by LC-MS/MS

## No. C161

Veterinary drugs are used for therapeutic, metaphylactic, prophylactic and growth promotion purposes. To provide an assurance that food from animals is safe with regards to residues of veterinary medicines, regulatory authorities have established Maximum Residue Limits (MRL's) for certain drugs in tissues and animal species. pharmacologically active compounds identified by regulatory authorities have been prohibited and their hazardousness at all levels are being considered (EU regulation EC 37/2010; Commission Decision 2003/181/EC; 21CFR Part 556 Tolerances for Residues of New Animal Drugs in Food). In this article, we describe how a triple quadrupole mass spectrometer, which is both highly sensitive and selective, contributes to reducing false positive and false negative reporting when using a measurement mode called MRM Spectrum mode. MRM Spectrum mode acquires a high number of fragment ion transitions for each target compound and generates fragmentation spectra that can be used in routine library searching and compound verification using reference library match scores.

David Baker \*1, Laetitia Fages \*2, Eric Capodanno \*2, Neil Loftus \*1 \*1 : Shimadzu, Manchester, UK \*2 : Phytocontrol, Nimes, France

#### Samples and Analysis Conditions

Liquid chromatograph

Samples of beef, egg, honey, milk and salmon were extracted and spiked with veterinary drugs in the calibration range of 0.001 to 0.1 mg/kg. Repeatability was assessed at low and high concentrations. Samples were measured using Shimadzu's Nexera X2 UHPLC and LCMS-8060 triple quadrupole mass spectrometer (Table 1 and 2). Over 200 veterinary drugs were targeted and over 2,000 MRM transitions in both ESI +/-were monitored during a gradient elution time of 12 minutes.

#### Table 1 UHPLC Conditions

Liquid Cirolilatography					
UHPLC	Nexera LC system				
Analytical column	Restek Biphenyl (100 $\times$ 2.1, 2.7 $\mu$ m)				
Column temperature	40 °C				
Flow rate	0.4 mL/minute	0.1 % formic acid 0.5 mM ammonium formate			
Solvent A	0.1 % formic ac solution				
Solvent B	0.1 % formic acid in methanol				
Binary Gradient	Time (mins)	%B	Time (mins)	%B	
	0.00	2	14.60	2	
	12.50	100	17.50	Stop	
	14.50	100			

#### Table 2 MS/MS Acquisition Parameters

Mass spectrometry					
Mass spectrometer	Shimadzu LCMS-8060				
Pause time/dwell time	1 msec/3 msec				
Polarity switching time	Pos/neg switching time set to 5 msec				
Scope	218 drugs in positive ion mode (including internal standards)				
	11 drugs in negative ion mode				
	Structure Analytics (in house development tool)				
Source temperatures (interface; heat block; DL)	350 °C; 300 °C; 150 °C				
Gas flows (nebulising; heating; drying)	3 L/min; 10 L/min; 10 L/min				

### Advantages of MRM Spectrum Mode

The measurement method can be easily set using the MRM optimization tool and measurement window (MRM Synchronization) settings of LabSolutions LCMS. The method achieves high data densities and a high data sampling rate across each elution peak. This approach generates a consistent loop time and sampling rate producing reliable quantitation and peak integration. It also provides great operator-friendliness in routine simultaneous analysis of veterinary drugs by enhancing flexibility in qualifier and quantifier ion selection. The number of fragment ion transitions generated from a single precursor ion is limited only by the chemical structure of the veterinary drug.

#### Results

MRM Spectrum mode was used to acquire a high number of fragment ion transitions for each veterinary drug target. For chlortetracycline, 11 precursorfragment ion transitions were acquired using optimized collision energies (Fig. 1). Acquiring a high number of fragment ion transitions enables generation of fragmentation spectra which can be used in library searching and compound verification for each veterinary drug. (Chlortetratcycline is a tetracycline class of antimicrobials. According to the Sixth ESVAC report published in 2016, of the overall sales of antimicrobials in the 29 EU countries in 2014, the largest amount, expressed as a proportion of mg/PCU, was accounted for by tetracyclines (33.4%). This is followed by penicillins (25.5%) and sulfonamides Chlortetracycline was selected as a (11.0 %). representative target).




Fig. 1 Utilization of MRM Spectrum Mode (Chlortetracycline)

Fig. 2 shows the MRM reference spectrum for chlortetracycline with assigned fragment structures. The MRM Spectrum mode is a measurement mode which combines MRM with the generation of a product ion spectrum. The product ion spectrum can be used for compound identification by searching a library.

As the collision energy was optimized for each fragment ion to generate a product ion spectrum, the library spectrum is highly specific and selective.




Fig. 2 MRM Reference Spectrum with Assigned Fragment Structures (Chlortetracycline)

%RSD

### ■ Library Identification using MRM Spectrum Mode




Fig. 3 Library Searchable MRM Spectra in Different Matrices Spiked at 10 pg/µL (Chlortetracycline)

Fig. 4 shows the MRM spectra and the n=10 measurement results of four compounds for salmon extract spiked with virginiamycin S1 at a concentration of 10 pg/μL. The library match score was above 99 in all injections (MRM spectra of injections 1, 5 and 10 are

3.74

3.04

indicated). Also, the %RSD for oxytetracycline, sulfadimethoxine, ormetoprim, and virginiamycin spiked into salmon extract (n=10; 10 pg/uL) acquired using a conventional 2-MRM method was compared with that of the MRM spectrum method.




Fig. 4 MRM Spectra and n=10 Results of Salmon Extract Spiked with Virginiamycin S1 at 10  $pg/\mu L$ 

1.46

1.54

1.18

0.91

1.65

1.49

### Quantitation Results using MRM Spectrum Mode

To assess the robustness of the MRM Spectrum mode, the same sample was repeatedly injected. The method used complies with the identification criteria set out in the EU guidelines SANTE/11945/2015 that require the retention time and the ion ratio from at least 2 MRM ion ratios to be within acceptable tolerance limits. The absolute response and signal variability were

compared to those of the MRM Spectrum mode (Fig. 4). Both methods resulted in a variance of less than 4 %RSD (n=10 for each method; 10 pg/uL spiked into salmon matrix). Fig. 5 indicates MRM spectra and the calibration curve obtained for sulfamerazine as an example of quantitation results.




Fig. 5 MRM Spectra and Calibration Curve of Sulfamerazine (1 pg/ $\mu L$  to 100 pg/ $\mu L$ )

### Conclusion

The level of confidence in compound identification and verification was increased by using a higher number of MRM transitions for each veterinary drug target and thereby reducing false negative and false positive reporting. Although the number of transitions for each target is dependent upon the chemical structure of the target, typically more than 10 transitions can be monitored for each compound. MRM Spectrum mode combines conventional quantitation with the

generation of a high quality product ion spectrum which can be used to achieve highly reliable compound identification and verification by library searching. In this research, use of the MRM Spectrum mode was examined by quantifying and identifying 212 veterinary drugs (the method included 2,009 MRM transitions). Limits of detection, linearity or repeatability were not compromised compared to a conventional 2-MRM method.



Shimadzu Corporation www.shimadzu.com/an/

For Research Use Only. Not for use in diagnostic procedures.

This publication may contain references to products that are not available in your country. Please contact us to check the availability of these products in your country.

The content of this publication shall not be reproduced, altered or sold for any commercial purpose without the written approval of Shimadzu. Company names, product/service names and logos used in this publication are trademarks and trade names of Shimadzu Corporation or its affiliates, whether or not they are used with trademark symbol "TM" or "6". Third-party trademarks and trade names may be used in this publication to refer to either the entities or their products/services. Shimadzu disclaims any proprietary interest in trademarks and trade names other than its own.

The information contained herein is provided to you "as is" without warranty of any kind including without limitation warranties as to its accuracy or completeness. Shimadzu does not assume any responsibility or liability for any damage, whether direct or indirect, relating to the use of this publication. This publication is based upon the information available to Shimadzu on or before the date of publication, and subject to change without notice.

First Edition: Aug. 2017